The treatment of Cushing's disease

R Pivonello, M De Leo, A Cozzolino… - Endocrine …, 2015 - academic.oup.com
Abstract Cushing's disease (CD), or pituitary-dependent Cushing's syndrome, is a severe
endocrine disease caused by a corticotroph pituitary tumor and associated with increased …

Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis

K Chwalisz, MC Perez, D DeManno, C Winkel… - Endocrine …, 2005 - academic.oup.com
Selective progesterone receptor modulators (SPRMs) represent a new class of
progesterone receptor ligands. SPRMs exert clinically relevant tissue-selective …

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

M Fleseriu, BMK Biller, JW Findling… - The Journal of …, 2012 - academic.oup.com
Context: Cushing's syndrome (CS) is a disorder associated with significant morbidity and
mortality due to prolonged exposure to high cortisol concentrations. Objective: Our objective …

Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis

AF Glasier, ST Cameron, PM Fine, SJS Logan… - The Lancet, 2010 - thelancet.com
Background Emergency contraception can prevent unintended pregnancies, but current
methods are only effective if used as soon as possible after sexual intercourse and before …

Cancer metastasis chemoprevention prevents circulating tumour cells from germination

X Xie, Y Li, S Lian, Y Lu, L Jia - Signal transduction and targeted …, 2022 - nature.com
The war against cancer traces back to the signature event half-a-century ago when the US
National Cancer Act was signed into law. The cancer crusade costs trillions with …

[HTML][HTML] Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression

R Liu, P Shi, Z Nie, H Liang, Z Zhou, W Chen… - Theranostics, 2016 - ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is currently the most malignant subtype of breast
cancers without effective targeted therapies. Mifepristone (MIF), a drug regularly used for …

A comprehensive review of the pharmacologic management of uterine leiomyoma

TD Lewis, M Malik, J Britten… - BioMed research …, 2018 - Wiley Online Library
Uterine leiomyomata are the most common benign tumors of the gynecologic tract impacting
up to 80% of women by 50 years of age. It is well established that these tumors are the …

Medical abortion

D Costescu, E Guilbert, J Bernardin, A Black… - Journal of Obstetrics and …, 2016 - Elsevier
Objective This guideline reviews the evidence relating to the provision of first-trimester
medical induced abortion, including patient eligibility, counselling, and consent; evidence …

Review of medical abortion using mifepristone in combination with a prostaglandin analogue

C Fiala, KG Danielsson - Contraception, 2006 - Elsevier
Induced abortion is still a major health problem in the world and the most frequently
performed intervention in obstetrics and gynecology with an estimated total of 46 million …

Mifepristone (RU 486) in Cushing's syndrome

S Johanssen, B Allolio - European Journal of Endocrinology, 2007 - academic.oup.com
Context Mifepristone (RU 486) blocks the action of cortisol by binding to the glucocorticoid
receptor and, therefore, is of potential therapeutic value in Cushing's syndrome. However …